The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4626-4635

  Su, Hsun Cheng ^a   Ramkissoon, Kevin ^a   Doolittle, Janet ^b   Clark, Martha ^a   Khatun, Jainab ^a   Secrest, Ashley ^a   Wolfgang, Matthew C ^a   Giddings, Morgan C ^a,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; METHYLMALONATE SEMIALDEHYDE DEHYDROGENASE (ACYLATING); SUCCINATE SEMIALDEHYDE DEHYDROGENASE;

ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; GENE DISRUPTION; GENE MUTATION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MODULATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; PSEUDOMONAS AERUGINOSA; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSPOSON; UPREGULATION;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; CIPROFLOXACIN; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; METHYLMALONATE-SEMIALDEHYDE DEHYDROGENASE (ACYLATING); MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

EID: 78049246321     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00762-10     Document Type: Article

References (52)

1. Akasaka, T., M. Tanaka, A. Yamaguchi, and K. Sato. 2001. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob. Agents Chemother. 45:2263-2268.
2. Anderl, J. N., J. Zahller, F. Roe, and P. S. Stewart. 2003. Role of nutrient limitation and stationary-phase existence in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 47:1251-1256.
3. Andrews, J. M. 2001. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(Suppl. 1):5-16.
4. Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik, and S. Leibler. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625.
5. Bandow, J. E., H. Brotz, L. I. Leichert, H. Labischinski, and M. Hecker. 2003. Proteomic approach to understanding antibiotic action. Antimicrob. Agents Chemother. 47:948-955.
6. Bosso, J. A. 1989. Use of ciprofloxacin in cystic fibrosis patients. Am. J. Med. 87:123S-127S.
7. Brazas, M. D., and R. E. Hancock. 2005. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:3222-3227.
8. Breidenstein, E. B., B. K. Khaira, I. Wiegand, J. Overhage, and R. E. Hancock. 2008. Complex ciprofloxacin resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered susceptibility. Antimicrob. Agents Chemother. 52:4486-4491.
9. Cirz, R. T., B. M. O'Neill, J. A. Hammond, S. R. Head, and F. E. Romesberg. 2006. Defining the Pseudomonas aeruginosa SOS response and its role in the global response to the antibiotic ciprofloxacin. J. Bacteriol. 188:7101-7110.
10. EUCAST. 2003. Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by broth microdilution. EUCAST discussion document E.Dis. 5.1. European Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland.
11. Fung-Tomc, J. C., E. Gradelski, L. Valera, B. Kolek, and D. P. Bonner. 2000. Comparative killing rates of fluoroquinolones and cell wall-active agents. Antimicrob. Agents Chemother. 44:1377-1380.
12. Giddings, M. C., A. A. Shah, R. Gesteland, and B. Moore. 2003. Genome-based peptide fingerprint scanning. Proc. Natl. Acad. Sci. U. S. A. 100:20-25.
13. Gomez, M. I., and A. Prince. 2007. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7:244-251.
14. Gorg, A., C. Obermaier, G. Boguth, A. Harder, B. Scheibe, R. Wildgruber, and W. Weiss. 2000. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037-1053.
15. Govan, J. R., and V. Deretic. 1996. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol. Rev. 60:539-574.
16. Higgins, P. G., A. C. Fluit, D. Milatovic, J. Verhoef, and F. J. Schmitz. 2003. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 21:409-413.
17. Hooper, D. C. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl. 2):S24-S28.
18. Jacobs, M. A., A. Alwood, I. Thaipisuttikul, D. Spencer, E. Haugen, S. Ernst, O. Will, R. Kaul, C. Raymond, R. Levy, L. Chun-Rong, D. Guenthner, D. Bovee, M. V. Olson, and C. Manoil. 2003. Comprehensive transposon mutant library of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 100:14339-14344.
19. Jalal, S., O. Ciofu, N. Hoiby, N. Gotoh, and B. Wretlind. 2000. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob. Agents Chemother. 44:710-712.
20. Keren, I., D. Shah, A. Spoering, N. Kaldalu, and K. Lewis. 2004. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J. Bacteriol. 186:8172-8180.
21. Kohanski, M. A., D. J. Dwyer, B. Hayete, C. A. Lawrence, and J. J. Collins. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810.
22. Kureishi, A., J. M. Diver, B. Beckthold, T. Schollaardt, and L. E. Bryan. 1994. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob. Agents Chemother. 38:1944-1952.
23. Kussell, E., R. Kishony, N. Q. Balaban, and S. Leibler. 2005. Bacterial persistence: a model of survival in changing environments. Genetics 169:1807-1814.
24. Levin, B. R., and D. E. Rozen. 2006. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4:556-562.
25. Lewis, K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56.
26. Li, T. K., and L. F. Liu. 1998. Modulation of gyrase-mediated DNA cleavage and cell killing by ATP. Antimicrob. Agents Chemother. 42:1022-1027.
27. Li, Y., and Y. Zhang. 2007. PhoU is a persistence switch involved in persister formation and tolerance to multiple antibiotics and stresses in Escherichia coli. Antimicrob. Agents Chemother. 51:2092-2099.
28. Lieberman, D., and D. Lieberman. 2003. Pseudomonal infections in patients with COPD: epidemiology and management. Am. J. Respir. Med. 2:459-468.
29. Lopez, E., and J. Blazquez. 2009. Effect of subinhibitory concentrations of antibiotics on intrachromosomal homologous recombination in Escherichia coli. Antimicrob. Agents Chemother. 53:3411-3415.
30. Lynch, C., P. Courvalin, and H. Nikaido. 1997. Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob. Agents Chemother. 41:869-871.
31. Manno, G., M. Cruciani, L. Romano, S. Scapolan, M. Mentasti, R. Lorini, and L. Minicucci. 2005. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre. Int. J. Antimicrob. Agents 25:193-197.
32. Mouneimne, H., J. Robert, V. Jarlier, and E. Cambau. 1999. Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:62-66.
33. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859.
34. O'Farrell, P. Z., H. M. Goodman, and P. H. O'Farrell. 1977. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell 12:1133-1141.
35. Oliver, A., B. R. Levin, C. Juan, F. Baquero, and J. Blazquez. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233.
36. Perkins, D. N., D. J. Pappin, D. M. Creasy, and J. S. Cottrell. 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567.
37. Poole, K. 2007. Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39:162-176.
38. Proctor, R. A., and A. von Humboldt. 1998. Bacterial energetics and antimicrobial resistance. Drug Resist. Update 1:227-235.
39. Pro-Q Diamond. 2005. Gel staining protocol. Invitrogen, Carlsbad, CA. http://www.interactivebioscience.cz/admin/-docs/protokol%20- %20Invitrogen%20ProQ%20Phosphoprotein%20Gel%20Staining.pdf.
40. Regoes, R. R., C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin. 2004. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48:3670-3676.
41. Reinhardt, A., T. Kohler, P. Wood, P. Rohner, J. L. Dumas, B. Ricou, and C. van Delden. 2007. Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients. Antimicrob. Agents Chemother. 51:1341-1350.
42. Riesenfeld, C., M. Everett, L. J. Piddock, and B. G. Hall. 1997. Adaptive mutations produce resistance to ciprofloxacin. Antimicrob. Agents Chemother. 41:2059-2060.
43. Schulenberg, B., R. Aggeler, J. M. Beechem, R. A. Capaldi, and W. F. Patton. 2003. Analysis of steady-state protein phosphorylation in mitochondria using a novel fluorescent phosphosensor dye. J. Biol. Chem. 278:27251-27255.
44. Schweizer, H. P. 2003. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet. Mol. Res. 2:48-62.
45. Su, H. C., C. A. Hutchison III, and M. C. Giddings. 2007. Mapping phosphoproteins in Mycoplasma genitalium and Mycoplasma pneumoniae. BMC Microbiol. 7:63.
46. Tatusov, R. L., N. D. Fedorova, J. D. Jackson, A. R. Jacobs, B. Kiryutin, E. V. Koonin, D. M. Krylov, R. Mazumder, S. L. Mekhedov, A. N. Nikolskaya, B. S. Rao, S. Smirnov, A. V. Sverdlov, S. Vasudevan, Y. I. Wolf, J. J. Yin, and D. A. Natale. 2003. The COG database: an updated version includes eukaryotes. BMC Bioinformatics 4:41.
47. Van Eldere, J. 2003. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J. Antimicrob. Chemother. 51:347-352.
48. Walsh, C. 2000. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781.
49. Wiuff, C., R. M. Zappala, R. R. Regoes, K. N. Garner, F. Baquero, and B. R. Levin. 2005. Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations. Antimicrob. Agents Chemother. 49:1483-1494.
50. Wolfgang, M. C., B. R. Kulasekara, X. Liang, D. Boyd, K. Wu, Q. Yang, C. G. Miyada, and S. Lory. 2003. Conservation of genome content and virulence determinants among clinical and environmental isolates of Pseudomonas aeruginosa. Proc. Natl. Acad. Sci. U. S. A. 100:8484-8489.
51. Yonezawa, M., M. Takahata, N. Matsubara, Y. Watanabe, and H. Narita. 1995. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1970-1972.
52. Zavascki, A. P., A. L. Barth, J. F. Fernandes, A. L. Moro, A. L. Goncalves, and L. Z. Goldani. 2006. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase- mediated multidrug resistance: a prospective observational study. Crit. Care 10: R114.